• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. Journal of Biological Sciences
  2. Vol 6 (6), 2006
  3. 1053-1058
  • Online First
  • Current Issue
  • Previous Issues
  • More Information
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

Journal of Biological Sciences

Year: 2006 | Volume: 6 | Issue: 6 | Page No.: 1053-1058
DOI: 10.3923/jbs.2006.1053.1058

Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend



Total views 171

Search


Authors


Rifat-uz-Zaman


Keywords


  • Hepatitis B
  • hepatitis B vaccine
  • recombinant vaccines
  • immunization
Research Article

Comparative Immunogenicity of Commercially Available Recombinant Vaccines Against Hepatitis B in Human Urban Population of Bahawalpur District, Pakistan

Rifat-uz-Zaman
The immunogenicity profiles of the recombinant hepatitis B vaccines commercially available in Pakistan were compared to Engerix-B® in a double-blind, prospective equivalence study. A total of 744 subjects (449 male, 295 female) of different age group and professions (randomly selected) of urban areas of Bahawalpur district were included in this study. Population was divided in six different groups (children, young and adult of either sex) and each group was administered (intramuscularly) one brand of vaccine (0, 1 and 6 month schedule). Children groups were vaccinated by 10 μg while young and adults groups by 20 μg of respective vaccine. The participants had blood samples taken (3-times; at the time of second dose, one and six months after third dose). The seroprotection; geometric mean titer (mIU mL-1) of six different vaccine used, were found maximum 1880.46±12.48 with Amvax B and minimum 1790.62±18.26 with Hepa-B-vac in children group, from 1897.43±17.26 (Engirex-B) to 1815.46±12.74 (Hepa-B-vac) in young group and from 1881.75±10.97 (Amvax-B®) to 1729.82±8.85 (Hepa-B-vac) in adult group. The antibody titers <10 mIU mL-1 were found highest (3.8%) with Hepa-B-vac® and lowest (2.4%) with Amvax-B® and Hepavax-Gene®. Antibody titers 10<100, 100<1000 and >1000 mIU mL-1 were observed 14.56 (Hepa-B-vac®) to 9.1% (Amvax-B®), 40.56 (Heberbiovac) to 39.15% (Hepavax-Gene) and 48.8 (Engirex-B) to 41.61% (Hepa-B-vac), respectively. The study concluded that all the recombinant hepatitis B vaccines tested were equipotent and similar in immunogenicity to Engerix-B® in the human urban population of Bahawalpur-Pakistan.
PDF References Citation

How to cite this article

Rifat-uz-Zaman, 2006. Comparative Immunogenicity of Commercially Available Recombinant Vaccines Against Hepatitis B in Human Urban Population of Bahawalpur District, Pakistan . Journal of Biological Sciences, 6: 1053-1058.

DOI: 10.3923/jbs.2006.1053.1058

URL: https://scialert.net/abstract/?doi=jbs.2006.1053.1058

Related Articles

Association Between ABO Blood/ Rhesus Grouping and Hepatitis B and C: A Case-control Study

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved